VA Hampton Medical Center, Hampton, VA (AM); VA Connecticut Healthcare System, West Haven (AM, AJA); Department of Psychiatry, Yale School of Medicine, New Haven (AM, AC, AJA); VA New England Mental Illness Research and Education Center, West Haven, CT (AM, AJA).
J Addict Med. 2019 Jan/Feb;13(1):7-22. doi: 10.1097/ADM.0000000000000443.
: Topiramate is a non-benzodiazepine anticonvulsant medication with multi-faceted pharmacologic action. It has emerged as an efficacious pharmacotherapeutic option for the treatment of addiction, especially alcohol use disorder (AUD). We present a broad narrative review of the putative mechanism of action and clinical utility of topiramate with regard to AUD and other substance use disorders. Collective evidence suggests topiramate is an effective treatment option in AUD, with notable efficacy in reducing harmful drinking patterns in AUD. Though not currently approved by the United States Food and Drug Administration for the indication of AUD, topiramate should be considered as a pharmacological treatment option with high utility among AUD patients. Early pharmacogenetic studies raise the intriguing possibility of identifying patients likely to respond to topiramate using genetic testing, and initial studies show that topiramate may also be useful in treating cocaine use disorder, smoking cessation and behavioral addictions. However, further research is needed in all these areas.
托吡酯是一种非苯二氮䓬类抗惊厥药物,具有多方面的药理作用。它已成为治疗成瘾的有效药物治疗选择,特别是酒精使用障碍 (AUD)。我们广泛综述了托吡酯在 AUD 和其他物质使用障碍方面的作用机制和临床应用。综合证据表明,托吡酯是 AUD 的有效治疗选择,在减少 AUD 中有害饮酒模式方面具有显著疗效。尽管托吡酯目前未获得美国食品和药物管理局 (FDA) 对 AUD 的批准,但它应该被视为 AUD 患者具有高实用价值的药物治疗选择。早期的药物遗传学研究提出了一个有趣的可能性,即通过基因测试来识别可能对托吡酯有反应的患者,初步研究表明,托吡酯也可能对治疗可卡因使用障碍、戒烟和行为成瘾有用。然而,在所有这些领域都需要进一步的研究。